Related Experiment Video
Updated: Jun 25, 2025

15:04
Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
Published on: May 20, 2016
10.9K
Gold Nanoparticles: Tunable Characteristics and Potential for Nasal Drug Delivery
Aida Maaz1, Ian S Blagbrough1, Paul A De Bank1,2,3
1Department of Life Sciences, University of Bath, Bath BA2 7AY, UK.
Pharmaceutics
|May 25, 2024
Summary
Gold nanourchins (GNUs) were formulated into a nasal inhaler for direct nose-to-brain drug delivery. This novel approach shows promising olfactory targeting and nasal deposition for potential therapeutic applications.
Area of Science:
- Nanotechnology
- Materials Science
- Pharmacology
Background:
- Direct nose-to-brain drug delivery (NTBDD) offers a promising alternative to systemic administration.
- Gold nanostructures, like gold nanourchins (GNUs), have potential in biomedical applications due to their unique properties.
- Developing stable and effective delivery systems for intranasal administration is crucial for successful NTBDD.
Purpose of the Study:
- To prepare gold nanourchins (GNUs) using a seed-mediated method.
- To formulate GNUs into a pressurized metered dose inhaler (pMDI) for nasal delivery.
- To investigate the olfactory targeting potential and nasal deposition of the GNU-pMDI formulation for direct nose-to-brain drug delivery (NTBDD).
Main Methods:
- Gold nanourchins (GNUs) were synthesized using dopamine hydrochloride and silver nitrate.
- A pMDI formulation containing GNUs, water, ethanol, and HFA134a propellant was developed.
- Aerosol performance, nasal deposition in a human nasal replica, and cell viability (RPMI 2650) were evaluated.
Main Results:
- The prepared GNUs remained stable during storage and lyophilization.
- The pMDI formulation demonstrated good aerosolization performance with intact GNUs.
- 13% of particles were deposited beyond the nasal valve, with 5.6% recovered from the olfactory region.
- The formulation showed excellent compatibility with the RPMI 2650 nasal cell line.
Conclusions:
- The developed GNU-HFA-based pMDI formulation is stable and suitable for intranasal drug delivery.
- The formulation exhibits potential for olfactory targeting, enabling direct nose-to-brain drug delivery (NTBDD).
- This approach represents a promising strategy for targeted drug delivery to the brain via the nasal route.

